Consortium invests $30m in series-B round for Eyevensys

Boehringer Ingelheim Venture Fund, which closed on €100m in 2010, is the corporate venture fund of Germany-based pharmaceutical company Boehringer Ingelheim.

The series-B financing round includes participation from existing investors Pontifax, BPI France, CapDecisif and Inserm Transfert Initiative, as well as new investors Global Health Sciences and Pureos Bioventures.

The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic non-infectious uveitis (NIU), including the launch of its Electro study.

Previous funding
CDC Entreprises, alongside Inserm Transfert and CapDecisif Management, provided a first €1.6m round for the business in 2012. A year later, Boehringer Ingelheim Venture Fund invested in the group, marking the beginning of the company's next funding round, which would be completed by 2013, targeting a value in excess of €5m. Previous investors also participated in the round.

Healthcare-dedicated investment firm Pontifax Venture Capital led a series-A funding round for Eyevensys in 2016, amounting to €9m. Pontifax joined an existing pool of investors, which included Boehringer Ingelheim Venture Fund, BPI France, CapDecisif, and Inserm Transfert. The round brought the total raised by Eyevensys to €10.8m, €1.9m of which was public financing provided by BPI.

Company
Founded in 2009, Eyevensys is a clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases. It recently opened a wholly owned US subsidiary in Fort Worth, Texas. All US operations will be managed from this location, though the Eyevensys headquarters will remain in Paris.

People
Eyevensys – Patricia Zilliox (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• BPI France